Received Mar 31, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 273H3 | — |
administration of the second dose of Havrix before the 6-month interval; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a 18-month-old female patient who received HAV (Havrix 720) (batch number 273H3, expiry date 19-JUN-2027) for prophylaxis. Previously administered products included Havrix (received first dose on an unknown date). On 23-MAR-2026, the patient received the 2nd dose of Havrix 720. On 23-MAR-2026, an unknown time after receiving Havrix 720, the patient experienced drug dose administration interval too short (Verbatim: administration of the second dose of Havrix before the 6-month interval). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 24-MAR-2026 Reporter called to report the administration of the second dose of Havrix before the 6 month interval. The vaccination dates for the first dose was not asked and no further details were provided.